ProMIS Neurosciences Inc. Common Shares (ON) (PMN) is a publicly traded Healthcare sector company. As of May 21, 2026, PMN trades at $10.75 with a market cap of $93.58M and a P/E ratio of -0.47. PMN moved +0.00% today. Year to date, PMN is +43.24%; over the trailing twelve months it is -19.24%. Its 52-week range spans $6.27 to $39.75. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces PMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ProMIS Neurosciences Secures $175M PIPE Financing, Funds Fully Enrolled Phase 1b Trial: ProMIS Neurosciences raised $175 million in PIPE financing to fund its fully enrolled 144-participant Phase 1b PRECISE-AD trial and operations through 2027. A blinded six-month interim analysis of safety and biomarker trends is due early Q3 2026, with unblinded 12-month top-line data expected early 2027.
| Metric | Value |
|---|---|
| Price | $10.75 |
| Market Cap | $93.58M |
| P/E Ratio | -0.47 |
| EPS | $-22.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $39.75 |
| 52-Week Low | $6.27 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-39.72M |
| Gross Margin | 0.00% |
1 analysts cover PMN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.